EP1255812A1 - Process for the production of non-human embryos of high-genetic value and of predetermined sex - Google Patents
Process for the production of non-human embryos of high-genetic value and of predetermined sexInfo
- Publication number
- EP1255812A1 EP1255812A1 EP01902306A EP01902306A EP1255812A1 EP 1255812 A1 EP1255812 A1 EP 1255812A1 EP 01902306 A EP01902306 A EP 01902306A EP 01902306 A EP01902306 A EP 01902306A EP 1255812 A1 EP1255812 A1 EP 1255812A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- spermatozoa
- process according
- comprised
- semen
- flow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 97
- 230000008569 process Effects 0.000 title claims abstract description 57
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 210000002257 embryonic structure Anatomy 0.000 title claims abstract description 15
- 210000000287 oocyte Anatomy 0.000 claims abstract description 28
- 238000000684 flow cytometry Methods 0.000 claims abstract description 18
- 238000003744 In vitro fertilisation Methods 0.000 claims abstract description 15
- 238000000338 in vitro Methods 0.000 claims abstract description 11
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 38
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 claims description 22
- 210000000349 chromosome Anatomy 0.000 claims description 15
- 241000283690 Bos taurus Species 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 14
- 238000011534 incubation Methods 0.000 claims description 12
- 230000008014 freezing Effects 0.000 claims description 9
- 238000007710 freezing Methods 0.000 claims description 9
- 238000010186 staining Methods 0.000 claims description 9
- 239000007979 citrate buffer Substances 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 238000007865 diluting Methods 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 4
- 210000002459 blastocyst Anatomy 0.000 claims description 4
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 3
- 230000004899 motility Effects 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 210000000582 semen Anatomy 0.000 abstract description 43
- 230000002068 genetic effect Effects 0.000 abstract description 12
- 241001465754 Metazoa Species 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 27
- 239000000523 sample Substances 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 230000001488 breeding effect Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 239000004606 Fillers/Extenders Substances 0.000 description 8
- 238000009395 breeding Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 210000002593 Y chromosome Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000004163 cytometry Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000001540 sodium lactate Substances 0.000 description 4
- 229940005581 sodium lactate Drugs 0.000 description 4
- 235000011088 sodium lactate Nutrition 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000004135 Bone phosphate Substances 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 210000001766 X chromosome Anatomy 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- VBELMRDAQMYTOU-UHFFFAOYSA-N chembl1093419 Chemical compound OC1=CC(O)=CC=C1C(C(=C1)O)=CC2=C1OC1=CC(=O)C(C=3C(=CC(O)=CC=3)O)=CC1=N2 VBELMRDAQMYTOU-UHFFFAOYSA-N 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000003765 sex chromosome Anatomy 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108020001019 DNA Primers Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical compound N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000011045 prefiltration Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VXUGVISSBXKUEL-UHFFFAOYSA-N 2-hydroxypropanoic acid;2-oxopropanoic acid Chemical compound CC(O)C(O)=O.CC(=O)C(O)=O VXUGVISSBXKUEL-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0612—Germ cells sorting of gametes, e.g. according to sex or motility
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
Definitions
- a flow-cytometer consists of: one or more laser beams that intersect the sample; a hydrodynamic system that conveys the cells sample to be analysed to a flow stream of a liquid, iso-osmotic with the sample; a series of light detectors (photodiodes and/or photomultipliers); a computer for data analysis in real time.
- the analysis is based on the assessment of the light emitted from the cells under examination once they are intersected by the laser beam.
- Said cells are previously stained with fluorochromes that, when exposed to coherent laser light, emit a particular fluorescence. Fluorescence is amplified by photomultipliers and computer analyzed, using software suitable for signal optimisation and interpretation.
- the flow-cytometer due to its high sensitivity, measures the different amounts of DNA present in spermatozoa X in respect of spermatozoa Y (a difference that varies depending on the species) using dyes, such as Bisbenzimide Hoechst 33342 which binds to the adenine- and thymidine-rich DNA regions.
- dyes such as Bisbenzimide Hoechst 33342 which binds to the adenine- and thymidine-rich DNA regions.
- the following step i.e. sorting, allows the particles which are passing into the flow stream and which have been charged positively or negatively depending on their characteristics and to parameters previously set by the operator, to be separated.
- the sperm cells with a different amount of fluorescence are physically separated by two differently charged plates which attract them on the basis of their charge and which divert them into two different collectors.
- the collected and separated material may be re-analysed by letting it flow again in the stream.
- the amount of light refracted at a 90 degree angle which includes fluorescence
- the cells let in a flow stream acquire a rotational motion, which is directly proportional to the flow rate, evidence is provided that the thin portion of the spermatozoa head, when crossed by the laser beam, is predominantly turned towards the detector at a 0 degree angle, with production of a lower amount of light refracted at a 90 degree angle and, consequently, of a lower amount of fluorescence (Pinkel D. et al., 1982, ibidem).
- the British patent GB 2,145,112 describes a sexing method based on flow-cytometry which exploits the spermatozoa electric charging, performed in a suitable sheath liquid. The method is set up for fresh semen.
- the sexing process proposed therein is characterised by a series of modifications to the flow- cytometer (for example to the flow cell needle) which create a flow of oriented cells with the larger surface perpendicular to the laser beam.
- the orthogonally illuminated instrument is modified so to acquire also the fluorescence from light refracted at a 0 degree angle (normally used for particles dimensional assessment only), by replacing the common photodiode, which cannot detect low fluorescence levels, with a photomultiplier.
- Said modifications described in Johnson L.A. e Pinkel D., 1986, Cytometry 7:268-273, refers in particular the modification to the needle point which renders standardisation of the method more problematic. This is the reason why protocols have been drawn up in an attempt to minimise the detections variability.
- the process of the present patent application describes the separation of frozen semen, according to a different DNA content carried by the X and Y sex chromosomes, by flow-cytometry.
- the process object of the present application is characterised by specific and critical staining procedures.
- Sperm separation and collection allow an efficient in vitro fertilization (IVF).
- IVF in vitro fertilization
- the process is useful in the zootechnical industry for the production of non-human mammalian embryos of predetermined sex and of high-genetic value.
- the non-human embryos produced according to the process of the invention are endowed with a high-genetic value, as being obtained from gametes selected on the basis of the genetic characteristics of their donors.
- the semen selected by the genetic characteristics of the animal, is frozen according to standardized procedures laid down by the European Union. It is then carried wherever the production of high-genetic-value embryos is industrially useful and economically profitable.
- the frozen semen is promptly thawed and stained with a DNA specific fluorochrome such as Hoechst 33342 under conditions allowing the highest spermatozoa vitality. Then, it is separated by flow-cytometry into two spermatozoa subpopulations, one containing chromosome Y and the other containing chromosome X.
- Figure 1 shows the cytograms obtained as FL2/FL1 ratio (FL2: 0 degree angle fluorescence; FL1 : 90° angle fluorescence), which were obtained to select the region with the highest fluorescence in FL1 and representing the population of spermatozoa which cross the laser beam with their larger surface. The region of interest has been boxed.
- Figure 2 Histogram of fluorescence at a 90 degree angle, made on the region previously selected. The gate allowing the assessment only of the spermatozoa crossed by the laser beam in the larger sur ace and, therefore, with higher FL1 , has been marked.
- Figure 3 Histogram of fluorescence at a 0 degree angle of spermatozoa with higher FL1 selected by gating. It is shown that the two spermatozoa subpopulations are physically separated.
- the gate useful for sorting is the one that selects the two bimodal histogram tails of fluorescence in FL2: the tail on the left corresponds to the spermatozoa containing chromosome Y ( ⁇ DNA content, ⁇ fluorescence), and that on the right corresponds to the spermatozoa containing chromosome X (>DNA content, > fluorescence).
- Figure 4 Evaluation of the efficiency of the spermatozoa sorting procedure by a genetic-molecular : PCR (polymerase chain reaction). Amplification was performed on sorted samples DNA and with standard samples of Y sorted gametes DNA opportunely contaminated with female DNA, to obtain a standard curve. DNA primers specific for the Y chromosome (BRY4a) were used. After amplification 15 ⁇ l of reaction product were electrophoresed for 1 h at 80 Volt on 2% agarose gels and stained with ethidium bromide. Gels were visualized with a UV ligth source, photographed with Polaroid film, and product bands quantified. The band intensities were used to quantify the relative amount of Y chromosomal DNA in each sample compared against the standard curve.
- PCR polymerase chain reaction
- A DNA extracted from female blood
- B DNA extracted from female blood + DNA extracted from a pool of semen (corresponding to an enrichment of gametes carrying the Y chromosome of 10%)
- C DNA extracted from female blood + DNA extracted from a pool of semen (enrichment of 20%)
- D DNA extracted from female blood + DNA extracted from a pool of semen (enrichment of 30%)
- E DNA extracted from female blood + DNA extracted from a pool of semen (enrichment of 40%);
- F DNA extracted from a pool of semen (50% of Y);
- G DNA extracted from sorted semen (X spermatozoa);
- H DNA extracted from sorted semen (Y spermatozoa); I: negative control (water).
- Object of the present patent application is a process for sexing frozen semen by flow-cytometry.
- the new process is characterised by specific and critical staining, separation and collection conditions, which will be described hereinafter in detail.
- the semen sexed under the conditions described in the present patent application is endowed with a fertilising capacity useful for an effective in vitro fertilization (IVF) for the production of non-human mammalian embryos of predetermined sex (e.g. of cattle, buffaloes, horses, sheep, pigs, rodents).
- IVF effective in vitro fertilization
- the invention describes a process for the production of non-human high-genetic value embryos of predetermined sex derived from gametes of breeding mammalian species, which comprises the following steps: a) thawing out a frozen solution of genetically selected semen and diluting it; b) staining the spermatozoa with a DNA specific fluorescent dye; c) diluting out the sample; d) sorting the stained spermatozoa population by flow cytometry into a spermatozoa subpopulation containing chromosome X and into a spermatozoa subpopulation containing chromosome Y; e) in vitro homologous fertilisation of oocytes with one or the other spermatozoa subpopulation; f) incubation of fertilised oocytes into a mammalian culture medium.
- step a) of the process may be optionally preceded by a freezing step usually performed according to process well known in the art such as those officially acknowledged by the European Union.
- the semen is derived from animals which have been selected on the basis of their genetic characteristics and/or on the genetic characteristics of their progeny, as for example semen derived from bulls which are genetic fathers of cows producing very high amounts of milk and/or which were found, when tested, to be free from genetic diseases like the biochemical defect BLAD (Bovine Leukocyte Adhesion Deficiency) and/or DUMPS ( Deficiency of Uridine Monophosphate Synthase) in Halstain breed.
- BLAD Bovine Leukocyte Adhesion Deficiency
- DUMPS Deficiency of Uridine Monophosphate Synthase
- step a) of the process the frozen semen is promptly thawed, preferably in a thermostated water bath at 37°C for at least 30", then it is preferably diluted with a buffer solution at a preferred spermatozoa concentration comprised between 15 and 25x10 6 /ml, more preferably 18-22x10 6 spermatozoa/ml.
- the dilution buffer is preferably chosen according to the extender used for semen freezing.
- a citrate buffer is preferred when a solution such as the Laiciphos buffer containing milk-derived proteins is used as extender in the preparation of the frozen sperm, while a TALP (Tyrode's Albumin Lactate Pyruvate) Ca ++ and BSA free solution (whose composition will be specified ahead) is preferred when buffer solutions containing soya- (such as Biociphos) or egg yolk-derived proteins are used for the same purpose.
- a commonly used citrate buffer has the following composition: 109 mM tribasic bihydrated sodium citrate and 2.4 mM citric acid, in water.
- the process of the present invention utilizes thawed semen with a progressive motility (PM) not lower than 40% (per cent amount of spermatozoa with VAP (Velocity Average Path) > 25 ⁇ m/sec and STR (Straightness) > 0.8, according to WHO'S parameters (World Health Organization, 1992, Laboratory manual for the examination of human semen and sperm-cervical mucus interaction).
- PM progressive motility
- spermatozoa are stained in step b) of the process by incubation in a DNA specific fluorochrome dye solution.
- the dye used is Bisbenzimide Hoechst 33342, used at conditions able to maintain the spermatozoa vitality at an optimal level.
- This condition is achieved by the use of Bisbenzimide Hoechst 33342 in concentration of at least 50 ⁇ g/ml, preferably comprised between 70 and 180 ⁇ g/ml, even more preferably comprised between 80-120 ⁇ g/ml and for a time not longer than 30 minutes, preferably comprised between 10 and 20 minutes, more preferably 15 minutes, at a temperature ranging from 30°C to 38°C, more preferably 34°C-36°C, most preferred 35°C.
- the staining is performed by adding the fluorochrome at a final concentration of 100 ⁇ g/ml at the solution containing the spermatozoa, for a time of about 15 minutes, at a temperature of 35°C.
- sperm cells may be optionally washed with the same buffer used for the previous dilution.
- the sample is then further diluted with a protein-free buffer or with isotonic solutions.
- a protein-free buffer or with isotonic solutions According to a preferred embodiment of the invention, in step c) is used the same buffer as in step a), that are preferably a citrate buffer and/or an "enriched buffer solution", such as the TALP Ca ++ and BSA free solution.
- the composition of the TALP solution for in vitro fertilisation is known in the art (see Ball GB et al., Biol Reprod, 1983, 28:717-725). In the process of the invention, this solution is called TALP IVF and is the buffer of choice for in vitro fertilisation.
- the solution, as used in the method of the invention also for purposes different from IVF techniques, is modified and Calcium and/or BSA are not added. Other slight variations are introduced in the composition to maintain the optional osmolarity (comprised between 270-300 mOsm).
- composition of the preferred TALP Ca ++ and BSA free version is here reported: NaCI 6000 mg, KCI 230 g, Na 2 HPO 4 40 mg, MgCI 2 -6H 2 O 310 mg, hepes 4760 mg, sodium lactate 60% 3700 ⁇ l, kanamycin 75 mg, sodium piruvate 110 mg, PVA (polyvinyl alcohol) 1000 mg, NaHCO 3 420 mg, NaOH 420 mg, sterile H 2 O 1000 ml; pH 7.4, with an osmolarity comprised between 270-300 mOsm, preferably comprised between 280-290 mOsm. It is known that other slight variations of this solution may be introduced.
- sample is diluted at a preferred final ratio of 3:1 (sample:buffer).
- buffer solutions may be used to dilute the sample, as i.e. PBS or Tyrode's, according to the preferences related to the extender used for initial semen freezing, with the provision that no proteic component is added.
- preferred solutions are citrate buffer or TALP Ca ++ and BSA free buffer, by the use of which the total dissolution of the freezing extender is observed.
- Sperm separation is carried out by flow-cytometry with orthogonal illumination on apparatuses modified according to Johnson L.A., Pinkel D. (1986) Cytometry 7:268-273, e.g. the Epics V (Coulter) instrument.
- the method of the invention preferably employs the Becton-Dickinson FACS Vantage SE equipped with: i) a laser for the emission of UV light; ii) a MacroSORTTM head supporting a beveled needle as described in Johnson L.A., Pinkel D.
- the instrument with orthogonal illumination is modified to acquire also the fluorescence from light refracted at a 0 degree angle (normally used for particles dimensional assessment only), by replacing the common photodiode, which cannot detect low fluorescence levels, with a photomultiplier.
- the beveled needle allows to reduce or to eliminate the spermatozoa rotational motion, while the addition of a photomultiplier at 0 degree angle allows a more precise measurement of the fluorescence intensity.
- the addition of the Turbo Sort Plus Option is however optional, although preferred, allowing only to fasten the sorting procedure and to obtain a high number of sorted sperm cells/second.
- the efficiency of the instrument is further optimized by treatment of the sample according to the process.
- the sample is made to flow in the cytometer (step (d) of the process), where evaluation of the DNA content of the cells and sorting is performed.
- the solution used as entraining or "sheath" fluid is a protein-free buffer, preferably the same buffer used for the next step of in vitro fertilization (or a buffer fully compatible with it).
- An "enriched buffer solution”, such as the TALP Ca ++ and BSA free solution is preferably used.
- the composition of the TALP Ca ++ and BSA free solution has been reported above. This solution allows optimal results both in terms of flow stability and spermatozoa vitality and is usually the solution of choice (with the above mentioned modification on calcium and BSA concentrations) for the fertilisation step.
- sheath fluid i.e. PBS, Tris etc.
- sorting is performed by the flow-cytometer on the basis of the different amount of DNA present in spermatozoa carrying chromosome X with respect to spermatozoa carrying chromosome Y. This difference varies depending upon the mammalian species and is anyhow easily detectable by the instrument modified as said above.
- the process of the invention is performed on bovine gametic cells.
- Physical separation of the two subpopulations of gametic cells (spermatozoa), carrying one or the other sex-chromosome, also known as “sorting”, allows the cells which are charged positively or negatively depending on their characteristics and according to parameters previously set by the operator, to be collected separately.
- the separation is carried out through the "gating" procedure, according to defined parameters and separates cells with a different amount of fluorescence: two differently charged plates attract the particles on the basis of their charge and divert them to two collectors.
- the definition of the sorting parameters on the basis of the bimodality of the frequency distribution of the spermatozoa DNA content (Johnson L.A. ef al., 1989, Biol. Reprod.
- the sorting process is carried out preferably using a flow of approx. 25,000/30,000 cells/sec, when the Turbo Sort is used .
- the flux is approx. 1 ,500 cells/sec.
- each gametic cell is detected by causing each single spermatozoon to pass through a channel illuminated by UV light, preferably set at a wavelength comprised between 333 to 364 nm; the signal obtained is diverted to two different photomultipliers (FL1 and FL2).
- the fluorescence signal from the samples is preferably acquired and displayed by the software CellQuest run on MacOS 7.5.3. operating system.
- the sperm, separated into the two populations X and Y in TALP Ca ++ and BSA free buffer, is preferably collected in protein-coated test tubes, such as those obtained by incubating them in a TALP Ca ++ free (standard) solution containing 5% BSA, for at least 8 hrs.
- spermatozoa are collected, optionally concentrated, e.g. by centrifugation at 400xg, and used for the in vitro fertilisation (step (e) of the process of the invention) on primary non-mature (non-ovulated) oocytes.
- the oocytes are obtained, e.g. by in vivo ovum pick-up or from freshly slaughtered animals and are matured in vitro using suitable media, such as the commercially available M199, added with hormones and foetal calf serum in controlled temperature and atmosphere conditions.
- In vitro "matured" oocytes may be optionally treated with hyaluronidase to remove contaminating or "coating cells".
- the in vitro fertilisation (step (e) of the process) is carried out according to procedures known in the art: a particularly preferred method is the one described by Galli C. et al. in Animal production and Biotechnology, Proceedings of the 19th International Symposium on Zootechnics, 1994, 185-189.
- TALP IVF In Vitro Fertilsation
- the preferred ratio between sexed spermatozoa and oocytes is 5000:1 (sperm/oocytes), in a final volume of 50 ⁇ l.
- Incubation is performed for 18 hrs in an incubator at 5% CO 2 /air, according to methods well known in the art. After this incubation time the fertilized eggs are transferred into a cell culture medium such as SOF or M199, until the blastocyst stage is reached. However other commercially available media suitable for embryo development may be used for this incubation.
- the non-human embryos may be used at the blastocyst stage for the implatantion into surrogated mothers or may be frozen and used in any other moment and in any other place of interest.
- a further object of the present invention is represented by high-genetic value embryos, of predetermined sex, as produced in step f) of the process, obtainable by the process according to the invention. They may be used as such or after freezing. It should be noted that the values of these embryos are not limited to the single individual generated by the IVF but also, and more importantly, to the progeny that this single individual will generate and which will carry the genetic characteristics which have been selected for.
- step f) is followed by an optional stage of freezing of the embryo, performed according to known protocols.
- the convenience of the process of the invention is that all the sexing procedure and the in vitro fertilisation operations are performed into a laboratory fully equipped for both of them and they don't need to be performed on site in the breeding center usually equipped only for implantation of the embryo.
- the fertilised bovine oocyte is co- cultured on a cell monolayer, in the particular and preferred case of bovine oocytes, derived from bovine tubal epithelium.
- the embryo obtained may be frozen or directly re-implanted in substitute mothers for the later development growth or it may be analysed to confirm the efficiency of sperm sexing.
- the method, object of the present invention is preferably applied to the bovine species, but can be advantageously applied also to any other breeding mammalian species and in particular to ovine, equine and rodent species, such as: sheeps, buffalos, horses, goats, pigs, rodents, mice.
- the method of the present invention is effective for the production of embryos of predetermined sex of non-human mammalian species from frozen semen.
- the semen is selected on the basis of useful genetic characteristic of the individual or of the progeny derived and has therefore a high-genetic value.
- the process of the invention allows the choice of the individual carrying the useful genetic characteristics without time and geographical limitations, because of the use of frozen semen.
- the possibility to sex frozen semen allows the more efficient production of progeny aimed at particular purposes in the zootechnical industry or addressed to particular production lineage (i.e. female for milk production or male for meat production).
- the method of the invention allows a fertilisation efficiency still suitable for industrial purposes.
- the embryos obtainable by the process of the invention have a high-genetic value, as they are derived from genetically selected individuals according to characteristics useful in the zootechnical industry and more importantly, they can be produced entirely in the laboratory where they can be frozen and used in the breeding centre.
- EXPERIMENTAL PART The following examples show some of the practical applications of the process of the invention without representing any limitation. Instrumentation
- the FACS Vantage SE (Becton-Dickinson) is equipped for the sexing procedure with the following accessories: 1 ) Water-cooled argon laser, Coherent Innova 300C, with 333.6-363.8 nm bandpass filters; 2) Detectors: the photodiode is replaced by a photomultiplier (PMT) for the detection of fluorescence at a 0 degree angle (FL2); No.
- PMT photomultiplier
- the aforesaid modifications to the FACS Vantage are described in: Johnson L.A. and Pinkel D. in Cytometry 7:268-273, 1986; the modified items are available on the market as FACSVantage (Becton-Dickinson) additional kits.
- the modified instrument provides a cytogram which visualizes the different spermatozoa sub-populations obtained when the gametes, which have acquired a different orientation, flow through a laser beam. We were interested in the subpopulation that allows a more accurate analysis of the bimodality due to the different DNA content, since the spermatozoa are intersected by the laser beam in a perpendicular direction. Solutions used
- Bisbenzimide Hoechst 33342 stock solution (5 mg/ml): H 2 O or Tyrode's solution 400 ⁇ l, Hoechst 33342 (Sigma) 2 mg.
- the solution was prepared and divided into aliquots which were stored at -20°C.
- the solution was prepared and aliquoted in 25 ml stock and stored at +4°C.
- Lacmoid 1 % 100 mg Lacmoid, sterile H 2 O 5.5 ml, glacial acetic acid 4.5 ml. Filtered with 0.8 ⁇ m filter.
- Example 1 Vitality and dilution tests on Hoechst 33342-labelled samples Tests were conducted with various concentrations of Bisbenzimide Hoechst 33342: final 5 ⁇ g/ml, final 10 ⁇ g/ml and 100 ⁇ g/ml, with incubation times of 15, 60, 120, 240 e 300 min. The vitality of spermatozoa thawed as described in Example 2 was assessed after different incubation times, at different final dye concentrations: vitality was the highest after a 15-min staining with 100 ⁇ g/ml Bisbenzimide Hoechst 33342.
- the sample of stained spermatozoa was diluted with various solutions, such as PBS, Tyrode's solution, citrate buffer (109 mM tribasic bihydrated sodium citrate and 2.4 mM citric acid) and TALP Ca ++ and BSA free. Only these last two proved to be capable of completely dissolving the freezing extender, such to obtain an optical clearance allowing a better definition of the signal from the populations to be sorted by flow-cytometry.
- various solutions such as PBS, Tyrode's solution, citrate buffer (109 mM tribasic bihydrated sodium citrate and 2.4 mM citric acid) and TALP Ca ++ and BSA free. Only these last two proved to be capable of completely dissolving the freezing extender, such to obtain an optical clearance allowing a better definition of the signal from the populations to be sorted by flow-cytometry.
- the sorted sperm was collected according to different methods which were compared for the recovery efficiency: a) in test-tubes with extender based on Tris and egg yolk with or without BSA or in BSA-coated (saturated) test-tubes incubated overnight with TALP Ca ++ and BSA free pH 7.4, added with 5% BSA. The best results were obtained by collecting the spermatozoa in TALP Ca ++ and BSA free, pH 7.4, in test-tubes saturated with BSA, which maintains the spermatozoa vitality at an optimal level and does not interfere with the successive In Vitro Fertilisation steps. Conversely, the methods known in the art (e.g.
- Example 2 Sperm sexing and separation of two subpopulations carrying chromosomes X or Y Preparation of thawed samples
- the sexed semen was used for the following step on flow-cytometry only if its progressive motility was 40 % at minimum (measured as per cent amount of spermatozoa with VAP (Velocity Average Path) > 25 ⁇ m/sec and STR (straightness) > 0.8),
- the semen was diluted in a citrate buffer (109 mM tribasic bihydrated sodium citrate and 2.4 mM citric acid) or in TALP Ca ++ and BSA free to a spermatozoa concentration of 20x10 6 /ml. Then an aliquot of Bisbenzimide Hoechst 33342 solution (5 mg/ml in Tyrode's buffer/H 2 O) was added to obtain a final concentration of 100 ⁇ g/ml. The sample was then incubated at 35°C for 15 min. For fluorescence assessment and for the successive spermatozoa separation, the sample was caused to flow in the instrument using TALP Ca ++ and BSA free, pH 7.4, as sheath liquid. Fluorescence analysis By means of an argon laser, Innova 300C, rated at 150 mW, fluorochromatised spermatozoa were excited by 333.6-363.8 nm UV light.
- a citrate buffer 109 mM tribasic bihydrated sodium citrate and 2.4
- the semen sexing was checked on the sorted material by cytometric re-analysis or by genetic-molecular methods.
- the sexed material collected was re-analysed by flow cytometry.
- computer software it is possible to overlap the histograms of fluorescence in FL2, obtained from spermatozoa X and Y.
- the results obtained by this method indicate that in the sorted subpopulations the enrichment of spermatozoa containing the X or Y chromosome is always higher than 75%.
- a semi-quantitative approach based on PCR was also used to confirm the efficiency of sorting using DNA primers specific for the Y chromosome (BRY4a, see Peura et al., Theriogenology, 1999, 35:547 -555).
- the Y chromosome-specific primers corresponded to nucleotides 1159-1178 (5' primers) 5'-CTCAGCAAAGCACACCAGAC-3' and 1439-1459 (3' primers) 5- 'GAACTTTCAAGCAGCTGAGGC-3'.
- Image analysis of the fluorescent intensity of PCR amplified Y chromosome-specific DNA was used to quantify the relative amount of y chromosomal DNA in each sample. Fluorescent intensity of each sample was compared with that of a reference sample prepared from pooled unsexed ejaculate (pooled sperm).
- the standard curve consisting of 30 ng/ ⁇ l of female DNA (only XX) diluted with 30 ng/ ⁇ l pooled sperm DNA in different ratio (see Table 1 ). Table 1. Preparation of the standard for PCR amplification.
- the 50 ⁇ l per reaction contained 30 ng of DNA template, 1x PCR buffer (Perkin Elmer), 200 ⁇ M each dNTP, 1 ,5mM MgCI 2 , 250 mM of each primer and 1.25 U of Taq Gold polymerase (Perkin Elmer).
- the amplifications were carried out in a GeneAmp per System 9700 (PE Applied Biosystem).
- the samples were denaturated at 95 °C for 10 minutes followed by 20 cycles consisting of denaturation for 15 seconds at 95 °C, annealing for 15 seconds at 65 °C and primer extension at for 72 °C for 1 minute. After the last cycle the samples were incubated for a further 5 minutes at 72°C.
- 15 ⁇ l of reaction product were electrophoresed for 1 h at 80 Volt on 2% agarose gels, stained with ethidium bromide. Gels were visualized with a UV light source, photographed with Polaroid film, and product bands quantified.
- Example 4 In vitro fertilisation and pre-implant growth of fertilised oocytes
- the oocytes were added to TALP wash and freed from the spermatozoa and cells of the "corona radiata" by mechanical vortex motion.
- a few of said fertilised oocytes were put on an ethanol-washed slide, closed with a cover glass to check whether fertilisation had taken place.
- the slides were allowed to stand overnight in a fixative (ethanol/acetic acid 3:1 ). Then they were dyed by capillarity with 1 % lacmoid and promptly rinsed with 45% acetic acid. If fertilisation took place, the two male and female pronuclei and the penetrated spermatozoon tail can be viewed through a microscope. Otherwise, i.e. in the case of non- fertilised oocyte, the maturation of same is proved by the presence of a metaphase with a polar globule.
- the medium was replaced by adding the culture drop with 20 ⁇ l SOF, equilibrated in an incubator, and by sucking an equal amount of it. After two further days of culturing in SOF, this medium was replaced, according to the same procedure, by equilibrated medium M199. This medium will support the embryos development to the blastocytes stage, which will be reached on the two following days.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Reproductive Health (AREA)
- Animal Husbandry (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The process described herein concerns the production of non-human mammalian embryos of predetermined sex, with high-genetic value. The process uses frozen semen, frozen according to EU regulations, obtained from animals selected for their genetic characteristics at Semen Collection Centres, which is thawed and sexed by flow-cytometry. Sexed spermatozoa are used for the in vitro fertilisation of oocytes of a compatible animal species for the in vitro production of embryos of predetermined sex. The operating conditions of the present process allow the use of frozen semen.
Description
PROCESS FOR THE PRODUCTION OF NON-HUMAN EMBRYOS OF HIGH- GENETIC VALUE AND OF PREDETERMINED SEX Field of the invention
The technical fields of the invention are the in vitro fertilisation techniques for use in the zootechnical industry. Prior art
The broad diffusion of artificial fertilisation (AF) techniques allowed the zootechnic industry to improve the process for producing breeding animals selected on the basis of useful characteristics. Sex pre-selection techniques represent a further improvement of these procedures favouring either milk or meat production or both, according to the breeder's and to the market's needs. In fact, on the one hand it is possible to improve the selection either on the female line, i.e. for milk production or on the male line, i.e. for meat production, while on the other hand it is possible to control, reduce or even avoid sex-related genetic diseases. The possibility of semen selection and subdivision on the basis of the presence of different sex chromosomes (a procedure called sexing) is of most interest for the zootechnic world, as it enables the birth planning of the offspring in genetic centres of breeding cows and bulls. However, only with the development of flow-cytometry the process for male gametes pre-selection have been improved and standardised becoming industrially useful.
A flow-cytometer consists of: one or more laser beams that intersect the sample; a hydrodynamic system that conveys the cells sample to be analysed to a flow stream of a liquid, iso-osmotic with the sample; a series of light detectors (photodiodes and/or photomultipliers); a computer for data analysis in real time. The analysis is based on the assessment of the light emitted from the cells under examination once they are intersected by the laser beam. Said cells are previously stained with fluorochromes that, when exposed to coherent laser light, emit a particular fluorescence. Fluorescence is amplified by photomultipliers and computer analyzed, using software suitable for signal optimisation and interpretation. The flow-cytometer, due to its high sensitivity, measures the different amounts of DNA present in spermatozoa X in respect of spermatozoa Y (a difference that varies depending on the species) using dyes, such as
Bisbenzimide Hoechst 33342 which binds to the adenine- and thymidine-rich DNA regions.
The following step, i.e. sorting, allows the particles which are passing into the flow stream and which have been charged positively or negatively depending on their characteristics and to parameters previously set by the operator, to be separated. The sperm cells with a different amount of fluorescence are physically separated by two differently charged plates which attract them on the basis of their charge and which divert them into two different collectors. To check the separation efficiency, the collected and separated material may be re-analysed by letting it flow again in the stream.
By defining the sorting on the basis of the bimodality of the frequency distribution of the spermatozoa DNA content (Johnson L.A. et al., 1989, Biol. Reprod. 41 :199- 203) it is possible to quantify spermatozoa X and Y and subdivide them into two populations (X and Y). Consequently flow-cytometry proved to be valid not only for spermatozoa analysis but also for their physical separation (Garner D.L. ef al., 1983, Biol. Reprod. 28:312-321 ; Johnson L.A., 1991 , Reprod. Dom. Anim. 26:309- 314; Johnson L.A. et al. 1989, Biol. Reprod. 41 :199-203; Morell et al., 1988, Vet. Rec. 122:322-324). Epi-illuminated (frontally in respect of cells) flow-cytometers are favoured in the DNA study of spermatozoa (Pinkel ef al., 1982, Cytometry 1 :1-9), whereas those with orthogonal illumination should be adequately modified to make them fit for measuring the light diffracted at a 0 degree angle and not only - as it usually happens - the light refracted at 90 degree angle (Johnson L.A. and Pinkel D., 1986, Cytometry 7:268-273). In fact, in orthogonal illumination flow-cytometers the amount of light refracted at a 90 degree angle, which includes fluorescence, is greater when the laser beam intersects the spermatozoon through its larger surface, and is smaller when the laser beam crosses the spermatozoon through its narrower surface. Since the cells let in a flow stream acquire a rotational motion, which is directly proportional to the flow rate, evidence is provided that the thin portion of the spermatozoa head, when crossed by the laser beam, is predominantly turned towards the detector at a 0 degree angle, with production of a lower amount of light refracted at a 90 degree angle and, consequently, of a
lower amount of fluorescence (Pinkel D. et al., 1982, ibidem). Since the flow- cytometric detection is based on the fluorescence levels, the simple intersection of cells in a given position by a laser beam may compensate by defect a different fluorochromatisation level. The problem has been overcome with flow-cytometers which uses epi-illumination (with incandescent-arc light source) because, in this case, spermatozoa, whose conformation is flat, are lit up lengthwise and not crosswise (Pinkel D. et al., 1982, ibidem). The French patent FR 2,699,678 discloses a sexing method suitable for the sorting of cells without loading them with an electric charge, i.e. under conditions conceptually different from those described so far, conducted on a proper flow-cytometer (PAS III, Partec). The British patent GB 2,145,112 describes a sexing method based on flow-cytometry which exploits the spermatozoa electric charging, performed in a suitable sheath liquid. The method is set up for fresh semen. A method of semen sexing by flow-cytometry based on the principle of separation depending on the electric charge, and conducted with a flow cytometer of Epics V type (RTM, Coulter), is described in European patent EP 471 ,758. The sexing process proposed therein is characterised by a series of modifications to the flow- cytometer (for example to the flow cell needle) which create a flow of oriented cells with the larger surface perpendicular to the laser beam. Furthermore, the orthogonally illuminated instrument is modified so to acquire also the fluorescence from light refracted at a 0 degree angle (normally used for particles dimensional assessment only), by replacing the common photodiode, which cannot detect low fluorescence levels, with a photomultiplier. Said modifications, described in Johnson L.A. e Pinkel D., 1986, Cytometry 7:268-273, refers in particular the modification to the needle point which renders standardisation of the method more problematic. This is the reason why protocols have been drawn up in an attempt to minimise the detections variability. The steps taken concern on one hand the elimination of the spermatozoa rotational motion (achieved through tails elimination) and, to the other hand, the maximisation of the nucleus decompactation, which would allow a more precise measurement of the fluorescence intensity (Metezeau P., 1991 , Molecular Reprod. and Develop. 30:250-257).
Therefore the extensive patent and scientific literature published so far evidences that the methods and apparatus used for semen sexing by flow-cytometry are subject to continuous adjustments and improvements for always better standardisation and reproducibility of the results. In many cases their use has been described only for fresh semen. Summary of the invention
The process of the present patent application describes the separation of frozen semen, according to a different DNA content carried by the X and Y sex chromosomes, by flow-cytometry. The process object of the present application is characterised by specific and critical staining procedures. Sperm separation and collection allow an efficient in vitro fertilization (IVF). The process is useful in the zootechnical industry for the production of non-human mammalian embryos of predetermined sex and of high-genetic value. The non-human embryos produced according to the process of the invention are endowed with a high-genetic value, as being obtained from gametes selected on the basis of the genetic characteristics of their donors. This represents a great advancement in the zootechnical industry, especially when focused to the production of progenitor of high-genetic value progeny, for all the breeding and farming animals i.e. the bovine, ovine, equine rodent species, such as cattle, buffaloes, horses, sheep, pigs, mice etc..
According to the process of the present invention, the semen, selected by the genetic characteristics of the animal, is frozen according to standardized procedures laid down by the European Union. It is then carried wherever the production of high-genetic-value embryos is industrially useful and economically profitable. The frozen semen is promptly thawed and stained with a DNA specific fluorochrome such as Hoechst 33342 under conditions allowing the highest spermatozoa vitality. Then, it is separated by flow-cytometry into two spermatozoa subpopulations, one containing chromosome Y and the other containing chromosome X. Depending on the genetic characteristics needed in the breeding centre where the sperm is conveyed, either subpopulation is used for the in vitro fertilisation of homospecific oocytes and for the production of high-genetic value non-human embryos of predetermined sex.
Brief description of the figures
Figure 1 shows the cytograms obtained as FL2/FL1 ratio (FL2: 0 degree angle fluorescence; FL1 : 90° angle fluorescence), which were obtained to select the region with the highest fluorescence in FL1 and representing the population of spermatozoa which cross the laser beam with their larger surface. The region of interest has been boxed.
Figure 2: Histogram of fluorescence at a 90 degree angle, made on the region previously selected. The gate allowing the assessment only of the spermatozoa crossed by the laser beam in the larger sur ace and, therefore, with higher FL1 , has been marked.
Figure 3: Histogram of fluorescence at a 0 degree angle of spermatozoa with higher FL1 selected by gating. It is shown that the two spermatozoa subpopulations are physically separated. The gate useful for sorting is the one that selects the two bimodal histogram tails of fluorescence in FL2: the tail on the left corresponds to the spermatozoa containing chromosome Y (<DNA content, <fluorescence), and that on the right corresponds to the spermatozoa containing chromosome X (>DNA content, > fluorescence).
Figure 4: Evaluation of the efficiency of the spermatozoa sorting procedure by a genetic-molecular : PCR (polymerase chain reaction). Amplification was performed on sorted samples DNA and with standard samples of Y sorted gametes DNA opportunely contaminated with female DNA, to obtain a standard curve. DNA primers specific for the Y chromosome (BRY4a) were used. After amplification 15 μl of reaction product were electrophoresed for 1 h at 80 Volt on 2% agarose gels and stained with ethidium bromide. Gels were visualized with a UV ligth source, photographed with Polaroid film, and product bands quantified. The band intensities were used to quantify the relative amount of Y chromosomal DNA in each sample compared against the standard curve.
A: DNA extracted from female blood; B: DNA extracted from female blood + DNA extracted from a pool of semen (corresponding to an enrichment of gametes carrying the Y chromosome of 10%); C: DNA extracted from female blood + DNA extracted from a pool of semen (enrichment of 20%); D: DNA extracted from female blood + DNA extracted from a pool of semen (enrichment of 30%); E: DNA
extracted from female blood + DNA extracted from a pool of semen (enrichment of 40%); F: DNA extracted from a pool of semen (50% of Y); G: DNA extracted from sorted semen (X spermatozoa); H: DNA extracted from sorted semen (Y spermatozoa); I: negative control (water). Detailed description of the invention
Object of the present patent application is a process for sexing frozen semen by flow-cytometry. The new process is characterised by specific and critical staining, separation and collection conditions, which will be described hereinafter in detail. The semen sexed under the conditions described in the present patent application is endowed with a fertilising capacity useful for an effective in vitro fertilization (IVF) for the production of non-human mammalian embryos of predetermined sex (e.g. of cattle, buffaloes, horses, sheep, pigs, rodents).
According to a first embodiment, the invention describes a process for the production of non-human high-genetic value embryos of predetermined sex derived from gametes of breeding mammalian species, which comprises the following steps: a) thawing out a frozen solution of genetically selected semen and diluting it; b) staining the spermatozoa with a DNA specific fluorescent dye; c) diluting out the sample; d) sorting the stained spermatozoa population by flow cytometry into a spermatozoa subpopulation containing chromosome X and into a spermatozoa subpopulation containing chromosome Y; e) in vitro homologous fertilisation of oocytes with one or the other spermatozoa subpopulation; f) incubation of fertilised oocytes into a mammalian culture medium.
According to a particular embodiment of the present invention step a) of the process may be optionally preceded by a freezing step usually performed according to process well known in the art such as those officially acknowledged by the European Union. The semen is derived from animals which have been selected on the basis of their genetic characteristics and/or on the genetic characteristics of their progeny, as for example semen derived from bulls which are genetic fathers of cows producing very high amounts of milk and/or which
were found, when tested, to be free from genetic diseases like the biochemical defect BLAD (Bovine Leukocyte Adhesion Deficiency) and/or DUMPS ( Deficiency of Uridine Monophosphate Synthase) in Halstain breed. It may be derived from Semen Production Centres, were it is usually aliquoted, stored and frozen in 0.25- 0.5 ml paillettes (also known as "French" straws). The frozen semen is conveyed, at a constant and controlled temperature, wherever the production of high-genetic- value embryos is industrially useful and economically profitable, i.e. to various breeding centres, potentially without any limit of time and place. According to the process of the invention, in step a) of the process the frozen semen is promptly thawed, preferably in a thermostated water bath at 37°C for at least 30", then it is preferably diluted with a buffer solution at a preferred spermatozoa concentration comprised between 15 and 25x106/ml, more preferably 18-22x106 spermatozoa/ml. The dilution buffer is preferably chosen according to the extender used for semen freezing. In fact a citrate buffer is preferred when a solution such as the Laiciphos buffer containing milk-derived proteins is used as extender in the preparation of the frozen sperm, while a TALP (Tyrode's Albumin Lactate Pyruvate) Ca++ and BSA free solution (whose composition will be specified ahead) is preferred when buffer solutions containing soya- (such as Biociphos) or egg yolk-derived proteins are used for the same purpose. A commonly used citrate buffer has the following composition: 109 mM tribasic bihydrated sodium citrate and 2.4 mM citric acid, in water.
The process of the present invention utilizes thawed semen with a progressive motility (PM) not lower than 40% (per cent amount of spermatozoa with VAP (Velocity Average Path) > 25 μm/sec and STR (Straightness) > 0.8, according to WHO'S parameters (World Health Organization, 1992, Laboratory manual for the examination of human semen and sperm-cervical mucus interaction). According to the process of the invention, spermatozoa are stained in step b) of the process by incubation in a DNA specific fluorochrome dye solution. The dye used is Bisbenzimide Hoechst 33342, used at conditions able to maintain the spermatozoa vitality at an optimal level. This condition is achieved by the use of Bisbenzimide Hoechst 33342 in concentration of at least 50 μg/ml, preferably comprised between 70 and 180 μg/ml, even more preferably comprised between
80-120 μg/ml and for a time not longer than 30 minutes, preferably comprised between 10 and 20 minutes, more preferably 15 minutes, at a temperature ranging from 30°C to 38°C, more preferably 34°C-36°C, most preferred 35°C. According to a preferred embodiment the staining is performed by adding the fluorochrome at a final concentration of 100 μg/ml at the solution containing the spermatozoa, for a time of about 15 minutes, at a temperature of 35°C. After labelling, sperm cells may be optionally washed with the same buffer used for the previous dilution. The sample is then further diluted with a protein-free buffer or with isotonic solutions. According to a preferred embodiment of the invention, in step c) is used the same buffer as in step a), that are preferably a citrate buffer and/or an "enriched buffer solution", such as the TALP Ca++ and BSA free solution. By the use of the preferred solutions the total dissolution of the freezing extender is observed and a better definition of the spermatozoa populations to be read and sorted is obtained during flow-cytometry. The composition of the TALP solution for in vitro fertilisation (IVF) is known in the art (see Ball GB et al., Biol Reprod, 1983, 28:717-725). In the process of the invention, this solution is called TALP IVF and is the buffer of choice for in vitro fertilisation. The solution, as used in the method of the invention also for purposes different from IVF techniques, is modified and Calcium and/or BSA are not added. Other slight variations are introduced in the composition to maintain the optional osmolarity (comprised between 270-300 mOsm). When both BSA and calcium are lacking the solution is therefore called TALP Ca++ and BSA free and has essentially the same composition as the TALP IVF, and is perfectly compatible in case of mixing of the two. When used as diluting or sheath fluid for spermatozoa separation by flow- cytometry TALP lacks BSA and calcium. The composition of the preferred TALP Ca++ and BSA free version is here reported: NaCI 6000 mg, KCI 230 g, Na2HPO4 40 mg, MgCI2-6H2O 310 mg, hepes 4760 mg, sodium lactate 60% 3700 μl, kanamycin 75 mg, sodium piruvate 110 mg, PVA (polyvinyl alcohol) 1000 mg, NaHCO3 420 mg, NaOH 420 mg, sterile H2O 1000 ml; pH 7.4, with an osmolarity comprised between 270-300 mOsm, preferably comprised between 280-290 mOsm. It is known that other slight variations of this solution may be introduced.
The sample is diluted at a preferred final ratio of 3:1 (sample:buffer). It is known in the art, however that other buffer solutions may be used to dilute the sample, as i.e. PBS or Tyrode's, according to the preferences related to the extender used for initial semen freezing, with the provision that no proteic component is added. As in the previous dilution, preferred solutions are citrate buffer or TALP Ca++ and BSA free buffer, by the use of which the total dissolution of the freezing extender is observed. By the use of the preferred diluting solutions a better definition of the spermatozoa populations to be read and sorted is obtained. Sperm separation (sexing) is carried out by flow-cytometry with orthogonal illumination on apparatuses modified according to Johnson L.A., Pinkel D. (1986) Cytometry 7:268-273, e.g. the Epics V (Coulter) instrument. The method of the invention preferably employs the Becton-Dickinson FACS Vantage SE equipped with: i) a laser for the emission of UV light; ii) a MacroSORT™ head supporting a beveled needle as described in Johnson L.A., Pinkel D. (1986) Cytometry 7:268- 273; iii) two photomultipliers for fluorescence detection at 0 (an additional standard kit) and 90 degree angles, and suitable filters; iv) preferably the Turbo Sort Plus Option, consisting of a special fluid and electronic system that allows to achieve sorting pressure of up to 60 p.s.i. and sample flow rate of up to 40.000 particles/sec. The modifications to the flow-cytometer (for example the one to the flow cell needle) create a flow of oriented cells with the larger surface perpendicular to the laser beam. The instrument with orthogonal illumination is modified to acquire also the fluorescence from light refracted at a 0 degree angle (normally used for particles dimensional assessment only), by replacing the common photodiode, which cannot detect low fluorescence levels, with a photomultiplier.
Said modifications allow to increase the apparatus sensitivity: in particular the beveled needle allows to reduce or to eliminate the spermatozoa rotational motion, while the addition of a photomultiplier at 0 degree angle allows a more precise measurement of the fluorescence intensity. The addition of the Turbo Sort Plus Option is however optional, although preferred, allowing only to fasten the sorting procedure and to obtain a high number of sorted sperm cells/second. The efficiency of the instrument is further optimized by treatment of the sample
according to the process.
After dilution the sample is made to flow in the cytometer (step (d) of the process), where evaluation of the DNA content of the cells and sorting is performed. The solution used as entraining or "sheath" fluid is a protein-free buffer, preferably the same buffer used for the next step of in vitro fertilization (or a buffer fully compatible with it). An "enriched buffer solution", such as the TALP Ca++ and BSA free solution is preferably used. The composition of the TALP Ca++ and BSA free solution has been reported above. This solution allows optimal results both in terms of flow stability and spermatozoa vitality and is usually the solution of choice (with the above mentioned modification on calcium and BSA concentrations) for the fertilisation step. However, other buffer solutions may be used as sheath fluid, i.e. PBS, Tris etc., provided that they do not contain any proteic component. As said above, sorting is performed by the flow-cytometer on the basis of the different amount of DNA present in spermatozoa carrying chromosome X with respect to spermatozoa carrying chromosome Y. This difference varies depending upon the mammalian species and is anyhow easily detectable by the instrument modified as said above.
According to a preferred embodiment, the process of the invention is performed on bovine gametic cells. Physical separation of the two subpopulations of gametic cells (spermatozoa), carrying one or the other sex-chromosome, also known as "sorting", allows the cells which are charged positively or negatively depending on their characteristics and according to parameters previously set by the operator, to be collected separately. The separation is carried out through the "gating" procedure, according to defined parameters and separates cells with a different amount of fluorescence: two differently charged plates attract the particles on the basis of their charge and divert them to two collectors. The definition of the sorting parameters on the basis of the bimodality of the frequency distribution of the spermatozoa DNA content (Johnson L.A. ef al., 1989, Biol. Reprod. 41 :199-203) for spermatozoa carrying the chromosome X and for those carrying chromosome Y allows their subdivision into two populations. According to the methods of the invention the sorting process is carried out preferably using a flow of approx. 25,000/30,000 cells/sec, when the
Turbo Sort is used . Alternatively, when the Turbo Sort device is not used, the flux is approx. 1 ,500 cells/sec.
The fluorescence of each gametic cell is detected by causing each single spermatozoon to pass through a channel illuminated by UV light, preferably set at a wavelength comprised between 333 to 364 nm; the signal obtained is diverted to two different photomultipliers (FL1 and FL2).
The fluorescence signal from the samples is preferably acquired and displayed by the software CellQuest run on MacOS 7.5.3. operating system. The sperm, separated into the two populations X and Y in TALP Ca++ and BSA free buffer, is preferably collected in protein-coated test tubes, such as those obtained by incubating them in a TALP Ca++ free (standard) solution containing 5% BSA, for at least 8 hrs.
Spermatozoa are collected, optionally concentrated, e.g. by centrifugation at 400xg, and used for the in vitro fertilisation (step (e) of the process of the invention) on primary non-mature (non-ovulated) oocytes. The oocytes are obtained, e.g. by in vivo ovum pick-up or from freshly slaughtered animals and are matured in vitro using suitable media, such as the commercially available M199, added with hormones and foetal calf serum in controlled temperature and atmosphere conditions. In vitro "matured" oocytes may be optionally treated with hyaluronidase to remove contaminating or "coating cells".
According to a preferred embodiment, the in vitro fertilisation (step (e) of the process) is carried out according to procedures known in the art: a particularly preferred method is the one described by Galli C. et al. in Animal production and Biotechnology, Proceedings of the 19th International Symposium on Zootechnics, 1994, 185-189. According to said method, oocytes are incubated in a medium suitable for spermatozoa capacitation and for fertilisation, such as TALP IVF, whose composition is known in the art and is here reported for completeness: TALP IVF (In Vitro Fertilsation): NaCI 620 mg, KCI 23 mg, Na2HP04 4.7 mg, MgCI2-6H2O 10 mg, NaHCO3 220 mg, CaCI2-2H2O 39 mg, kanamycin 7.5 mg, 60% Na lactate 186 μl, sodium piruvate 11 mg, BSA fraction V (fatty acid free) 600 mg, heparin 0.12 mg, sterile H2O 100 ml; pH 7.3-7.4, mOsm=270-300. The preferred ratio between sexed spermatozoa and oocytes is 5000:1
(sperm/oocytes), in a final volume of 50 μl. Incubation is performed for 18 hrs in an incubator at 5% CO2/air, according to methods well known in the art. After this incubation time the fertilized eggs are transferred into a cell culture medium such as SOF or M199, until the blastocyst stage is reached. However other commercially available media suitable for embryo development may be used for this incubation. The non-human embryos may be used at the blastocyst stage for the implatantion into surrogated mothers or may be frozen and used in any other moment and in any other place of interest. A further object of the present invention is represented by high-genetic value embryos, of predetermined sex, as produced in step f) of the process, obtainable by the process according to the invention. They may be used as such or after freezing. It should be noted that the values of these embryos are not limited to the single individual generated by the IVF but also, and more importantly, to the progeny that this single individual will generate and which will carry the genetic characteristics which have been selected for.
As said previously, according to a preferred embodiment of the invention, step f) is followed by an optional stage of freezing of the embryo, performed according to known protocols. The convenience of the process of the invention, according to this preferred embodiment, is that all the sexing procedure and the in vitro fertilisation operations are performed into a laboratory fully equipped for both of them and they don't need to be performed on site in the breeding center usually equipped only for implantation of the embryo. Alternatively to the growth in cell culture medium, the fertilised bovine oocyte is co- cultured on a cell monolayer, in the particular and preferred case of bovine oocytes, derived from bovine tubal epithelium.
The embryo obtained may be frozen or directly re-implanted in substitute mothers for the later development growth or it may be analysed to confirm the efficiency of sperm sexing. The method, object of the present invention, is preferably applied to the bovine species, but can be advantageously applied also to any other breeding mammalian species and in particular to ovine, equine and rodent species, such as:
sheeps, buffalos, horses, goats, pigs, rodents, mice.
The method of the present invention is effective for the production of embryos of predetermined sex of non-human mammalian species from frozen semen. The semen is selected on the basis of useful genetic characteristic of the individual or of the progeny derived and has therefore a high-genetic value. The process of the invention allows the choice of the individual carrying the useful genetic characteristics without time and geographical limitations, because of the use of frozen semen. The possibility to sex frozen semen allows the more efficient production of progeny aimed at particular purposes in the zootechnical industry or addressed to particular production lineage (i.e. female for milk production or male for meat production).
Therefore the method described herein, allowing the use of frozen semen, represents an important technical achievement over the prior art methods where sexing is performed on fresh semen. In fact, in the method of the invention, potentially any semen with the desired characteristics can be used in any country and at any time, i.e. potentially without any time and place limit imposed by the use of fresh semen.
The method of the invention allows a fertilisation efficiency still suitable for industrial purposes. The embryos obtainable by the process of the invention, have a high-genetic value, as they are derived from genetically selected individuals according to characteristics useful in the zootechnical industry and more importantly, they can be produced entirely in the laboratory where they can be frozen and used in the breeding centre. EXPERIMENTAL PART The following examples show some of the practical applications of the process of the invention without representing any limitation. Instrumentation
The FACS Vantage SE (Becton-Dickinson) is equipped for the sexing procedure with the following accessories: 1 ) Water-cooled argon laser, Coherent Innova 300C, with 333.6-363.8 nm bandpass filters; 2) Detectors: the photodiode is replaced by a photomultiplier (PMT) for the detection of fluorescence at a 0 degree angle (FL2); No. 2 Hamamatsu photomultipliers for the simultaneous detection of
at a 90 degree angle scatter light and fluorescence emission (FL1 ); 3) Filters: 8/90 scatter dichroic filter, 488/10 scatter bandpass filter, 560 shortpass dichroic filter, 424/44 bandpass filter for FL1 (UV), 424/44 bandpass filter for FL2 (UV); 4) Turbo Sort Option, consisting of a special fluid and electronic system that allows to achieve sorting pressure of up to 60 p.s.i. and sample flow rate of up to 40.000 particles/sec; 5) Software: CellQUEST for data acquisition and analysis, on MacOS 7.5.3. operating system.
The main modifications to the Instrument with regard to the protocol of semen sexing were: 1. an additional standard kit, Forward Scatter Photomultiplier, whereby the photodiode collecting the light signal at a 0 degree angle (forward scatter) is replaced by a photomultiplier collecting and completing all fluorescence data emitted from the spermatozoa intersected by laser beam; 2. the installation of a modified needle, whereby a greater quantity of spermatozoa can be oriented in the same direction. The needle is inserted in a new MacroSORT™ head.
The aforesaid modifications to the FACS Vantage are described in: Johnson L.A. and Pinkel D. in Cytometry 7:268-273, 1986; the modified items are available on the market as FACSVantage (Becton-Dickinson) additional kits. The modified instrument provides a cytogram which visualizes the different spermatozoa sub-populations obtained when the gametes, which have acquired a different orientation, flow through a laser beam. We were interested in the subpopulation that allows a more accurate analysis of the bimodality due to the different DNA content, since the spermatozoa are intersected by the laser beam in a perpendicular direction. Solutions used
Bisbenzimide Hoechst 33342 stock solution (5 mg/ml): H2O or Tyrode's solution 400 μl, Hoechst 33342 (Sigma) 2 mg. The solution was prepared and divided into aliquots which were stored at -20°C. TALP Ca++ and BSA free: NaCI 6000 mg, KCI 230 mg, Na2HPO4 40 mg, MgCI2-6H2O 310 mg, hepes 4760 mg, 60% sodium lactate 3700 μl, kanamycin 75 mg, sodium piruvate 110 mg, PVA 1000 mg, NaHCO3 420 mg, NaOH 420 mg,
sterile H2O 1000 ml; pH 7.4 ; mOsm = 284. The solution was prepared and aliquoted in 25 ml stock and stored at +4°C.
TALP IVF (In Vitro Fertilsation): NaCI 620 mg, KCI 23 mg, Na2HPO4 4.7 mg, MgCI2*6H2O 10 mg, NaHCO3 220 mg, CaCI2 2H2O 39 mg, kanamycin 7.5 mg, 60% Na lactate 186 μl, sodium piruvate 11 mg, BSA fraction V (fatty acid free) 600 mg, heparin 0.12 mg, sterile H2O 100 ml; pH 7.3-7.4, mOsm=275. The solution was sterilised with 0.22 μm filter plus prefilter and was aliquoted in 1 ml stock and stored in liquid nitrogen. TALP wash: NaCI 7300 mg, KCI 235 mg, Na2HPO4 47 mg, MgCI2-6H2O 100 mg, NaHCO3 168 mg, hepes 2380 mg, 60% sodium lactate 1900 μl, kanamycin 75 mg, sodium piruvate 110 mg, CaCI2-2H2O 390 mg, BSA fraction V 6000 mg, sterile H2O 1000 ml; pH 7.3-7.4, mOsm=280. Aliquoted in 25 ml stock and stored at +4°C. SOF: CaCI2 2H2O 25.1 mg, MgCI2-6H2O 10 mg, NaCI 580 mg, KCI 53.84 mg, KH2PO4 16.2 mg, NaHCO3 220 mg, sodium piruvate 3.6 mg, hepes 476 mg, penicillin 6.3 mg, streptomycin 5 mg, 60% sodium lactate 47 μl, D-glucose 27 mg, BSA fraction V (fatty acid free) 1600 mg, glutamine 14.6 mg, non-essential amino acids 1 ml, essential amino acids 2 ml, sterile H2O 97 ml; pH 7.3-7.4, mOsm=280. Sterilised with 0.22 μm filter plus pre-filter. Aliquoted in 0.5 ml stock and stored in liquid nitrogen.
Lacmoid 1 %: 100 mg Lacmoid, sterile H2O 5.5 ml, glacial acetic acid 4.5 ml. Filtered with 0.8 μm filter.
Example 1 : Vitality and dilution tests on Hoechst 33342-labelled samples Tests were conducted with various concentrations of Bisbenzimide Hoechst 33342: final 5 μg/ml, final 10 μg/ml and 100 μg/ml, with incubation times of 15, 60, 120, 240 e 300 min. The vitality of spermatozoa thawed as described in Example 2 was assessed after different incubation times, at different final dye concentrations: vitality was the highest after a 15-min staining with 100 μg/ml Bisbenzimide Hoechst 33342. The sample of stained spermatozoa was diluted with various solutions, such as PBS, Tyrode's solution, citrate buffer (109 mM tribasic bihydrated sodium citrate and 2.4 mM citric acid) and TALP Ca++ and BSA free. Only these last two proved
to be capable of completely dissolving the freezing extender, such to obtain an optical clearance allowing a better definition of the signal from the populations to be sorted by flow-cytometry.
Various solutions were tested as sheath fluid: i.e. PBS, Tris pH 7, and TALP Ca++ and BSA free, pH 7.4. The last solution gave good results in terms of flow stability and spermatozoa vitality and because it did not interfere in the in vitro fertilisation (IVF) step in which TALP was always used.
The TALP Ca++ and BSA free, pH 7.4 solution and the citrate buffer were not added with BSA; this allowed a better flow stability with consequent improvement of the sorting condition and results. In fact, spermatozoa with sticking heads (doublets), which indicate alterations of the cell membrane, were detected only in the presence - and not in the absence - of BSA.
The sorted sperm was collected according to different methods which were compared for the recovery efficiency: a) in test-tubes with extender based on Tris and egg yolk with or without BSA or in BSA-coated (saturated) test-tubes incubated overnight with TALP Ca++ and BSA free pH 7.4, added with 5% BSA. The best results were obtained by collecting the spermatozoa in TALP Ca++ and BSA free, pH 7.4, in test-tubes saturated with BSA, which maintains the spermatozoa vitality at an optimal level and does not interfere with the successive In Vitro Fertilisation steps. Conversely, the methods known in the art (e.g. with extender based on Tris and egg yolk with or without BSA) maintain a good vitality of spermatozoa, but do not allow an easy recovery of same in the first IVF steps. Example 2: Sperm sexing and separation of two subpopulations carrying chromosomes X or Y Preparation of thawed samples
The frozen bovine semen was thawed in a water bath thermostated at 37°C for 2 min. The kinetic parameters of an aliquot of at least 200 spermatozoa was assessed by the system CASA Hamilton Thome mod. IVOS set as follows: frame acquired = 30, minimum contrast = 15, minimum cell size = 25, threshold straightness = 80, medium VAP cut-off = 25.0, low VAP cut-off = 24.9, low VSL cut-off = 20.0, non-motile head size = 60, non-motile head intensity = 50, 0.19 < static size limits < 5.55, 0.52 < static intensity limits < 10.00, 0 < static elongation
limits < 60.
The sexed semen was used for the following step on flow-cytometry only if its progressive motility was 40 % at minimum (measured as per cent amount of spermatozoa with VAP (Velocity Average Path) > 25 μm/sec and STR (straightness) > 0.8),
The semen was diluted in a citrate buffer (109 mM tribasic bihydrated sodium citrate and 2.4 mM citric acid) or in TALP Ca++ and BSA free to a spermatozoa concentration of 20x106/ml. Then an aliquot of Bisbenzimide Hoechst 33342 solution (5 mg/ml in Tyrode's buffer/H2O) was added to obtain a final concentration of 100 μg/ml. The sample was then incubated at 35°C for 15 min. For fluorescence assessment and for the successive spermatozoa separation, the sample was caused to flow in the instrument using TALP Ca++ and BSA free, pH 7.4, as sheath liquid. Fluorescence analysis By means of an argon laser, Innova 300C, rated at 150 mW, fluorochromatised spermatozoa were excited by 333.6-363.8 nm UV light.
From the cells caused to flow at 25.000-30.000 cells/sec, the fluorescence data, at 0 and 90 degrees, were acquired in 1024-channel histograms and cytograms. In particular the following was assessed: a) cytogram FL2 (fluorescence at 0°)/FL1 (fluorescence at 90°) for the selection of the higher-fluorescence region in FL1 (spermatozoa passing through the laser beam with their larger surface) (figure 1 ); b) histogram of fluorescence in FL1 , at a 90 degree angle, made on the region previously selected. The gate allowing the assessment only of the spermatozoa crossed by the laser beam in the larger surface and, therefore, with higher FL1 , has been marked in figure 2. c) histogram of fluorescence in FL2 of the subpopulation defined above for bimodality control (figure 3)
It is thus possible to collect and integrate all data concerning the fluorescence emitted in the various direction from the spermatozoa crossed by the laser beam in their larger surface (length-wise). The definition of the subpopulations to be sorted was carried out through gates
which select the two tails of the bimodal histogram of fluorescence in FL2: the tail on the left corresponds to the spermatozoa containing chromosome Y (lower DNA content and, therefore, lower fluorescence); the tail on the right corresponds to the spermatozoa containing chromosome X (higher DNA content and, therefore, higher fluorescence).
Collection of spermatozoa subpopulations X and Y
The spermatozoa sorted according to the procedure described above and collected in BSA-lined test-tubes, were concentrated by centrifuging at 400 g for 10 min. Once the surnatant was removed, the pellet volume was measured. Example 3: Control of the efficiency of Y and X sorting
The semen sexing was checked on the sorted material by cytometric re-analysis or by genetic-molecular methods.
In the first case, the sexed material collected was re-analysed by flow cytometry. By particular computer software, it is possible to overlap the histograms of fluorescence in FL2, obtained from spermatozoa X and Y. The results obtained by this method indicate that in the sorted subpopulations the enrichment of spermatozoa containing the X or Y chromosome is always higher than 75%. A semi-quantitative approach based on PCR (polymerase chain reaction) was also used to confirm the efficiency of sorting using DNA primers specific for the Y chromosome (BRY4a, see Peura et al., Theriogenology, 1999, 35:547 -555).
The Y chromosome-specific primers corresponded to nucleotides 1159-1178 (5' primers) 5'-CTCAGCAAAGCACACCAGAC-3' and 1439-1459 (3' primers) 5- 'GAACTTTCAAGCAGCTGAGGC-3'. Image analysis of the fluorescent intensity of PCR amplified Y chromosome-specific DNA was used to quantify the relative amount of y chromosomal DNA in each sample. Fluorescent intensity of each sample was compared with that of a reference sample prepared from pooled unsexed ejaculate (pooled sperm). The standard curve consisting of 30 ng/μl of female DNA (only XX) diluted with 30 ng/μl pooled sperm DNA in different ratio (see Table 1 ).
Table 1. Preparation of the standard for PCR amplification.
The 50 μl per reaction contained 30 ng of DNA template, 1x PCR buffer (Perkin Elmer), 200 μM each dNTP, 1 ,5mM MgCI2, 250 mM of each primer and 1.25 U of Taq Gold polymerase (Perkin Elmer).
The amplifications were carried out in a GeneAmp per System 9700 (PE Applied Biosystem). The samples were denaturated at 95 °C for 10 minutes followed by 20 cycles consisting of denaturation for 15 seconds at 95 °C, annealing for 15 seconds at 65 °C and primer extension at for 72 °C for 1 minute. After the last cycle the samples were incubated for a further 5 minutes at 72°C. After amplification 15 μl of reaction product were electrophoresed for 1 h at 80 Volt on 2% agarose gels, stained with ethidium bromide. Gels were visualized with a UV light source, photographed with Polaroid film, and product bands quantified. The band intensities were used to quantify the relative amount of Y chromosomal DNA in each sample compared against the standard curve. The data are shown in figure 4. As an indicative example see sample G were it is shown that in the subpopulation sorted for the X chromosome the enrichment of spermatozoa is higher than 90% as compared with the standard B where a 10% of Y DNA "contamination" is present.
The results obtained using both methods show that in the sorted subpopulations the enrichment of spermatozoa containing the X or Y chromosome is always
higher than 75% confirming the efficiency of the method.
Example 4: In vitro fertilisation and pre-implant growth of fertilised oocytes
In vitro fertilisation of oocytes matured in vitro was substantially performed according to Galli C, Aleandri R., Lazzari G., Animal production and Biotechnology, Proceedings of the 19th International Symposium of Zootechnics, 1994, 185-189. From a 500 μl TALP IVF drop, allowed to equilibrate in 5% CO2 incubator at 38°C for at least 30 min, an aliquot was taken equal to the sexed spermatozoa pellet volume (measured as described in Example 2) and replaced by it. Said solution was used to prepare 50 μl drops, which were covered with hot mineral oil, previously equilibrated in 5% CO2 incubator at 38°C overnight. Five mature oocytes, denuded of the cumulus oophorus by hyaluronidase, were added to each drop.
After incubation in 5% CO2 incubator at 38°C for 30 min., the oocytes were added to TALP wash and freed from the spermatozoa and cells of the "corona radiata" by mechanical vortex motion.
A few of said fertilised oocytes were put on an ethanol-washed slide, closed with a cover glass to check whether fertilisation had taken place. The slides were allowed to stand overnight in a fixative (ethanol/acetic acid 3:1 ). Then they were dyed by capillarity with 1 % lacmoid and promptly rinsed with 45% acetic acid. If fertilisation took place, the two male and female pronuclei and the penetrated spermatozoon tail can be viewed through a microscope. Otherwise, i.e. in the case of non- fertilised oocyte, the maturation of same is proved by the presence of a metaphase with a polar globule. Once oocytes were fertilised and denuded by vortex motion, they were cultured in SOF. To this end, two 20μl microdrops of said medium covered with mineral oil had to be prepared one day before in suitable containers (four-wells). Microdrops had to be equilibrated for one day in a 5% CO2 and 5% O2 incubator at 38°C. Denuded oocytes were added to the first wash drop; the still uncleaved oocytes (those being cleaved after 18 hrs indicate a parthenogenic activation) were soon transferred into the second drop (approx. 20 oocytes/drop) and fed to an O2 incubator. On the following day, the first cleavage of fertilised oocytes could already be observed; the uncleaved ones were transferred to the lateral wash
drop. Two days later, the medium was replaced by adding the culture drop with 20μl SOF, equilibrated in an incubator, and by sucking an equal amount of it. After two further days of culturing in SOF, this medium was replaced, according to the same procedure, by equilibrated medium M199. This medium will support the embryos development to the blastocytes stage, which will be reached on the two following days.
The results obtained from the in vitro fertilisation IVFs are shown in table 2. Table 2
Claims
CLAIMS 1. Process for the production of high-genetic value embryos of predetermined sex derived from gametes of non-human mammalian species, comprising the following steps: a) thawing a frozen solution of genetically selected spermatozoa and diluting it; b) staining the spermatozoa with a DNA specific fluorescent dye; c) diluting out the stained sample; d) sorting the stained spermatozoa population by flow-cytometry into a spermatozoa subpopulation containing chromosome X and into a spermatozoa subpopulation containing chromosome Y, using as a sheath fluid a protein free solution; e) in vitro homologous fertilisation of oocytes with one or the other spermatozoa subpopulation; f) incubation of fertilised oocytes into a mammalian cell culture medium.
2. The process according to claim 1 , wherein dilutions in step a) and in step c) are performed using protein free solutions
3. The process according to claim 2, wherein said protein free solution is a citrate buffer or TALP Ca++ and BSA free
4. The process according to claim 1 , wherein in step d) said protein-free sheath fluid is essentially the same buffer used for in vitro fertilisation.
5. The process according to claims 1-4, wherein spermatozoa DNA staining in step b) is performed with the fluorochrome bisbenzimide Hoechst 33342.
6. The process according to claim 5 wherein said staining is obtained after incubation in a solution comprising bisbenzimide Hoechst 33342 at a concentration higher than 50 μg/ml, for a time shorter or equal to 30', at a temperature comprised between 30°C and 38°C.
7. The process according to claim 6, wherein said concentration is comprised between 70 and 180 μg/ml.
8. The process according to claim 6-7, wherein the bisbenzimide Hoechst 33342 concentration is comprised between 80 and 120 μg/ml, said temperature is comprised between 34°C and 36 °C and said time is comprised between 13 and 17 minutes.
9. The process according to claim 8, wherein the thawing in step a) is performed by incubation of said frozen solution at a temperature of 37°C for a time of at least 30" (minute second).
10. The process according to claim 1 , wherein the dilution in step a) is such as to obtain a spermatozoa concentration comprised between 15 and 25x106 spermatozoa/ml.
11. The process according to claim 1 , wherein staining in step c) of the process is performed on spermatozoa having a progressive motility not lower than 40%.
12. The process according to claims 1-11 , wherein said sorting performed by flow cytometry in step d) of the process is carried out on the Becton-Dickinson FACS Vantage SE.
13. The process according to claim 1 , wherein incubation of the fertilized oocyte in step f) of the process is performed until the oocyte has reached the blastocyst stage.
14. The process according to claims 1-13 wherein step f) of the process is followed by freezing of the fertilized oocyte or blastocyst.
15. The process according to claim 1 , wherein the non-human mammalian species are selected from the group consisting of: ovine, bovine, equine or rodents.
16. The process according to claim 13, wherein the non-human mammalian specie is bovine.
17. Non human high-genetic value mammalian embryos of predetermined sex obtainable according to the process as in claims 1-16.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2000MI000030A IT1317724B1 (en) | 2000-01-14 | 2000-01-14 | PROCEDURE FOR THE PRODUCTION OF NON-HUMAN SEX EMBRYOS WITH A HIGH GENETIC VALUE. |
ITMI200030 | 2000-01-14 | ||
PCT/EP2001/000281 WO2001051612A1 (en) | 2000-01-14 | 2001-01-11 | Process for the production of non-human embryos of high-genetic value and of predetermined sex |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1255812A1 true EP1255812A1 (en) | 2002-11-13 |
Family
ID=11443662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01902306A Withdrawn EP1255812A1 (en) | 2000-01-14 | 2001-01-11 | Process for the production of non-human embryos of high-genetic value and of predetermined sex |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1255812A1 (en) |
AU (1) | AU2001230176A1 (en) |
IT (1) | IT1317724B1 (en) |
WO (1) | WO2001051612A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2264428B1 (en) | 1997-01-31 | 2017-05-03 | Xy, Llc | Optical apparatus with focussing reflector for converging radiation onto a flow of particles |
US6149867A (en) | 1997-12-31 | 2000-11-21 | Xy, Inc. | Sheath fluids and collection systems for sex-specific cytometer sorting of sperm |
NZ509434A (en) | 1998-07-30 | 2004-03-26 | Univ Colorado State Res Found | Equine system for non-surgical artificial insemination |
US7208265B1 (en) | 1999-11-24 | 2007-04-24 | Xy, Inc. | Method of cryopreserving selected sperm cells |
EP2258169B1 (en) * | 2000-05-09 | 2019-07-10 | Xy, Llc | Method for isolating X-chromosome bearing and Y-chromosome bearing populations of spermatozoa |
US7713687B2 (en) | 2000-11-29 | 2010-05-11 | Xy, Inc. | System to separate frozen-thawed spermatozoa into x-chromosome bearing and y-chromosome bearing populations |
AU2002237689B2 (en) | 2000-11-29 | 2008-01-10 | Xy, Llc. | System to separate frozen-thawed spermatozoa into X-chromosome bearing and Y-chromosome bearing populations |
US8486618B2 (en) | 2002-08-01 | 2013-07-16 | Xy, Llc | Heterogeneous inseminate system |
WO2004012837A2 (en) | 2002-08-01 | 2004-02-12 | Xy, Inc. | Low pressure sperm cell separation system |
BRPI0313476B1 (en) | 2002-08-15 | 2015-06-23 | Xy Llc | High resolution flow cytometer |
US7169548B2 (en) | 2002-09-13 | 2007-01-30 | Xy, Inc. | Sperm cell processing and preservation systems |
MX345106B (en) | 2003-03-28 | 2017-01-16 | Inguran Llc * | Apparatus, methods and processes for sorting particles and for providing sex-sorted animal sperm. |
MXPA05010478A (en) | 2003-03-28 | 2005-12-15 | Monsanto Technology Llc | Process for the staining of sperm. |
CA2566749C (en) | 2003-05-15 | 2017-02-21 | Xy, Inc. | Efficient haploid cell sorting for flow cytometer systems |
BRPI0509466A (en) | 2004-03-29 | 2007-09-11 | Monsanto Technology Llc | use of a composition which regulates oxidation / reduction reactions intracellularly and / or extracellularly in a sperm staining or classification process |
EP2260854A1 (en) * | 2004-03-29 | 2010-12-15 | Inguran, LLC | Sperm suspensions for sorting into x or y chromosome-bearing enriched populations |
EP2269617B1 (en) | 2004-07-22 | 2016-04-27 | Inguran, LLC | Process for enriching a population of sperm cells |
DE102005044530B4 (en) * | 2004-09-16 | 2010-02-18 | Masterrind Gmbh | Method for the sex-specific selection of mammalian spermatozoa |
CN101793641B (en) * | 2010-04-14 | 2011-09-28 | 内蒙古蒙牛繁育生物技术股份有限公司 | Fluorescent staining method for separating dairy cow sperms |
AU2013325222B2 (en) | 2012-10-05 | 2016-06-23 | Inguran, Llc | Methods of processing sperm for sex sorting |
US10620213B2 (en) | 2012-10-05 | 2020-04-14 | Inguran, Llc | High pressure sperm sorting and flow cytometer methods |
CN116211532A (en) * | 2013-03-15 | 2023-06-06 | 英格朗公司 | Methods of increasing genetic value in male or female lines using sexed sperm |
CN114015705A (en) * | 2021-11-28 | 2022-02-08 | 华中科技大学同济医学院附属协和医院 | Sex selection method for mouse in-vitro fertilization breeding |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE142788T1 (en) * | 1989-05-10 | 1996-09-15 | Us Agriculture | PROCEDURE FOR SELECTING THE GENDER OF THE OFFSPRING |
US6071689A (en) * | 1997-12-31 | 2000-06-06 | Xy, Inc. | System for improving yield of sexed embryos in mammals |
-
2000
- 2000-01-14 IT IT2000MI000030A patent/IT1317724B1/en active
-
2001
- 2001-01-11 WO PCT/EP2001/000281 patent/WO2001051612A1/en active Application Filing
- 2001-01-11 AU AU2001230176A patent/AU2001230176A1/en not_active Abandoned
- 2001-01-11 EP EP01902306A patent/EP1255812A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0151612A1 * |
Also Published As
Publication number | Publication date |
---|---|
ITMI20000030A1 (en) | 2001-07-14 |
IT1317724B1 (en) | 2003-07-15 |
ITMI20000030A0 (en) | 2000-01-14 |
WO2001051612A1 (en) | 2001-07-19 |
AU2001230176A1 (en) | 2001-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001051612A1 (en) | Process for the production of non-human embryos of high-genetic value and of predetermined sex | |
AU623016B2 (en) | Method to preselect the sex of offspring | |
Johnson | Sex preselection by flow cytometric separation of X and Y chromosome-bearing sperm based on DNA difference: a review | |
EP2269617B1 (en) | Process for enriching a population of sperm cells | |
Johnson et al. | Preimplantation diagnosis: Gender preselection in humans? Flow cytometric separation of X and Y spermatozoa for the prevention of X-linked diseases | |
Blondin et al. | Analysis of bovine sexed sperm for IVF from sorting to the embryo | |
US9879221B2 (en) | Method of in-vitro fertilization with spermatozoa separated into X-chromosome and Y-chromosome bearing populations | |
US20050064383A1 (en) | Methods and apparatus for producing gender enriched sperm | |
JP2006502707A5 (en) | ||
Kawarasaki et al. | Verification of flow cytometorically-sorted X-and Y-bearing porcine spermatozoa and reanalysis of spermatozoa for DNA content using the fluorescence in situ hybridization (FISH) technique | |
NL8401137A (en) | METHOD FOR MAKING GENETIC MATERIAL VISIBLE | |
Marquant-Leguienne et al. | Practical measures to improve in vitro blastocyst production in the bovine | |
Jo et al. | Effect of antibodies binding to Y chromosome-bearing sperm conjugated with magnetic nanoparticles on bull sperm characteristics | |
US20110236923A1 (en) | Method for staining and sorting of a small volume of sperm | |
Samardzija et al. | Optimization of sperm for in vitro production of bovine embryos | |
CA2778245A1 (en) | Methods and systems for reducing dna fragmentation in a population of sperm cells | |
Bulshawareb et al. | Sperm sexing and its application in camel reproduction-a review | |
Rajaram et al. | Evaluation of Sperm Viability and Acrosomal Integrity by Flow Cytometry Analysis in Jersey Crossbred Bulls | |
WO2020191064A1 (en) | Method for improved sperm cell populations | |
Mir et al. | Sperm sexing by flow cytometry–past improvements and future prospects: A review | |
HUE029701T2 (en) | Process for enriching a population of sperm cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020809 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100615 |